Immunovant ends cutaneous lupus program after phase 2 flop
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
Useful takeaways from this story.
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.